Brief: Absci Initiates IND-Enabling Studies for ABS-101

Feb 21 (Reuters) - Absci Corp  ABSI.O :
    * ABSCI INITIATES IND-ENABLING STUDIES FOR ABS-101, A
POTENTIAL
BEST-IN-CLASS ANTI-TL1A ANTIBODY DE NOVO DESIGNED AND OPTIMIZED
USING GENERATIVE AI
    * ABSCI CORP - ABSCI EXPECTS TO SUBMIT AN IND FOR ABS-101 IN
Q1 OF
2025

Source text for Eikon:  ID:nGNX66fkGl 
Further company coverage:  ABSI.O 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on AbSci

See all news